510(k) Report

510(k) · Cleared

Cleared

Fujirebio Diagnostics Tumor Marker Control Model 108-20

K101809510(k) TraditionalCleared Oct 5, 201098-day reviewClass I21 CFR 862.1660

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026

Fujirebio Diagnostics,Inc. · JJY Multi-Analyte Controls, All Kinds (Assayed)

Cleared on Oct 5, 2010 as substantially equivalent to K082036 (Bio-Rad Laboratories, 2008) and 1 other predicate after a 98-day review. Its family tree reaches back 5 generations to 1994.

Decided
Oct 5, 2010
Review
98 days
Class
Class I
Product code
JJY
Recalls
None
Predicates
2

Its longest line of descent runs back 5 generations to K940433 (1994). 9 ancestors in all. No later device cites it as a predicate yet.

  1. Root · 5 generations backK940433 Doa Liquid Drugs of Abuse Controls Levls 2,3,& 4,G2,G3,& G4Medical Analysis Systems, Inc. · 1994
  2. 4 generations backK983807 Lyphochek Tumor Marker Control, Model #580Bio-Rad · 1998
  3. 3 generations backK992172 Lyphochek Tumor Marker Control, Model 580Bio-Rad · 1999
  4. 2 generations backK011579 Lyphochek Tumor Marker Control, Levels 1 and 2, 2ML, Model 580Bio-Rad · 2001
  5. 1 generation backK082036 Lyphochek Tumor Market Plus Control Level 1, 2 and 3 and MinipakBio-Rad Laboratories · 2008
  6. This deviceK101809 Fujirebio Diagnostics Tumor Marker Control Model 108-20Fujirebio Diagnostics,Inc. · 2010
View FIG. 1 as a table

Line of descent and top descendants

GenerationNumberDeviceApplicantDecidedRecalls
−5K940433Doa Liquid Drugs of Abuse Controls Levls 2,3,& 4,G2,G3,& G4Medical Analysis Systems, Inc.1994—
−4K983807Lyphochek Tumor Marker Control, Model #580Bio-Rad1998—
−3K992172Lyphochek Tumor Marker Control, Model 580Bio-Rad1999—
−2K011579Lyphochek Tumor Marker Control, Levels 1 and 2, 2ML, Model 580Bio-Rad2001—
−1K082036Lyphochek Tumor Market Plus Control Level 1, 2 and 3 and MinipakBio-Rad Laboratories2008—
0 (this device)K101809Fujirebio Diagnostics Tumor Marker Control Model 108-20Fujirebio Diagnostics,Inc.2010—

Other ancestors by year cleared

Year clearedDevicesWith a Class I recall
199710
200410
200810
201010
FIG. 1 — Lineage of K101809, 1994–2010Source: FDA 510(k) summaries, read by 510(k) Report · How lineage is built

Get the monthly Device Review Tracker

Notable FDA decisions, review times and new Class I recalls. See an issue.

Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.

Planning a device in JJY? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.

  • Candidate predicates for a device like this, rankedin the report
  • Recall history across each candidate’s familyin the report
Get a 510(k) Report

What was it cleared against? (2)

Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.

TypeNumberDeviceApplicantDecidedRecalls
*K082036Lyphochek Tumor Market Plus Control Level 1, 2 and 3 and Minipak
Summary page 1
…21 CFR 862.1660 Regulatory Class: Class I, reserved Product Code: JJY Predicate Device Bio-Rad Lyphochek® Tumor Marker Plus Control (K082036) For HE4: ARCHITECT HE4 Control Kit (K093957) Summary and Principle This quality control product can be used as an objective jud…
Bio-Rad Laboratories2008—
*K093957Architect HE4, Architect HE4 Calibrators and Architect HE4 Controls, Models 2, 2P54…
Summary page 1
…Class I, reserved Product Code: JJY Predicate Device Bio-Rad Lyphochek® Tumor Marker Plus Control (K082036) For HE4: ARCHITECT HE4 Control Kit (K093957) Summary and Principle This quality control product can be used as an objective judgment of the laboratory's procedures and pers…
Fujirebio Diagnostics,Inc.2010—

What descends from it?

No later submission names this one as a predicate yet.

Has anything in its family been recalled? (0 Class I)

No FDA recall names this device.

No ancestor or descendant has a Class I recall.

What does this lineage say?

  • The line of descent spans 16 years and passes through 4 companies; a new generation was cleared every 2.1 years on median.
  • 1 of the 9 ancestors has a recall of any class.

How does its category compare?

All JJY devices

JJY Multi-Analyte Controls, All Kinds (Assayed): FDA decisions, review times, recalls and adverse event reports over 20 years. 2010, this device’s year, is highlighted.

FDA decisions per year · JJY

3in 2017

2007: 112008: 72009: 82010: 102011: 142012: 132013: 162014: 102015: 42016: 12017: 3
2007high 16 (2013) · low 0 (2018)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · JJY

78in 2017

2007: 49 days median2008: 54 days median2009: 80 days median2010: 109 days median2011: 120 days median2012: 40 days median2013: 82 days median2014: 49 days median2015: 153 days median2017: 78 days median
2007high 153 (2015) · low 40 (2012)2026

Receipt to decision; years with fewer than 3 clearances left blank.

Recalls per year · JJY

2in 2025

2007: 52009: 22010: 62011: 12012: 32013: 22014: 22015: 12016: 32017: 42018: 32019: 42020: 62022: 32023: 32025: 22026 (partial year): 1
2007high 6 (2010) · low 0 (2008)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · JJY

13in 2025

2007: 22008: 12009: 32010: 32011: 62012: 202013: 52014: 42015: 42016: 132017: 122018: 72019: 12020: 72021: 12023: 42024: 12025: 13
2007high 20 (2012) · low 0 (2022)2025

MAUDE reports naming product code JJY, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
2007114952
200875401
200988023
20101010963
20111412016
20121340320
2013168225
2014104924
2015415314
20161—313
2017378412
20180—37
20190—41
20200—67
20210—01
20220—30
20230—34
20240—01
20250—213
20260—1—

What is it indicated for?

For In Vitro Diagnostic Use Only.

Fujirebio Diagnostics Tumor Marker Control is intended for use as an assayed control serum to monitor the precision of laboratory testing procedures for the analysis of AFP, CA15-3, CA19-9, CA125, CEA, Ferritin, HE4, PSA and Free PSA.

Indications for use as stated in the FDA summary.

Cite this page

510(k) Report. “K101809: Fujirebio Diagnostics Tumor Marker Control Model 108-20.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 3, 2026. https://510kreport.com/device/K101809

Report an extraction error

Tell us what is wrong; we check it against the FDA summary.

Are you the manufacturer?

Send a correction or an update to this page, for example a newer model or a public statement about a recall.

Record history
  • FDA decision record loaded May 2, 2026
  • Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
  • Lineage and recalls computed Nov 3, 2026
  • Page last updated Nov 3, 2026